Skip to main content

Table 1 Baseline demographic characteristics of study population

From: Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis - the effect of sex, Kellgren-Lawrence (KL) score, Body Mass Index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation

 

Placebo

0.6 mg sCT

0.8 mg sCT

p-value

Females

n = 12

n = 12

n = 13

-

Males

n = 11

n = 12

n = 13

 

Age (yrs)

65.7 (4.1)

64.5 (4.4)

66.7 (4.1)

0.43

 

64.6 (3.7)

65.3 (1.4)

64.0 (4.0)

0.58

YSM (yrs)

21 (8)

15 (6)

17 (6)

0.14

 

-

-

-

-

Height (cm)

168.2 (5.1)

167.2 (7.7)

161.9 (5.5)

0.03

 

177.8 (7.1)

176.9 (6.1)

175.5 (7.9)

0.73

Weight (kg)

76.4 (15.2)

73.4 (10.3)

78.7 (13.5)

0.61

 

89.0 (15.2)

85.2 (9.0)

91.9 (17.0)

0.51

BMI (kg/m2)

27.0 (5.6)

26.4 (4.1)

29.9 (3.9)

0.13

 

28.2 (5.1)

27.2 (2.4)

29.7 (4.4)

0.32

KL Index

I: 7 (30%)

I: 7 (29%)

I: 9 (35%)

0.80

 

II: 8 (35%)

II: 11 (46%)

II: 12 (46%)

 
 

III: 8 (35%)

III: 6 (25%)

III: 5 (19%)

 
  1. Values given are mean (SD). Years since menopause (YSM), body mass index (BMI), Kellgren-Lawrence (KL). The p-value column refers to the significance of the comparison of the three treatment groups.